comparemela.com

Latest Breaking News On - Clinical oncology - Page 8 : comparemela.com

Researchers report encouraging Phase 1 data for glioblastoma treatment

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.

New skin cancer vaccine being trialled by the NHS can halve the risk of dying or the deadly disease returning, study finds

Melanoma patients given Tecemotide alongside immunotherapy drug Keytruda were 49 per cent more likely to be alive three years later compared to those taking Keytruda alone.

vimarsana © 2020. All Rights Reserved.